The Advanced Prostate Cancer Consensus Conference 2015 recommended that progression should not be assessed on only increasing PSA and that the presence of at least 2 of the 3 criteria, including symptomatic progression, PSA progression, and radiographic progression, should be considered progression [20]. This evidence concerns the gene KLK3 and prostate carcinoma.